MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that its technology will be featured in over 10 clinical presentations and posters at the American Association of Wound Care (AAWC) 2022 Annual Conference, titled Technology in Wound Care. The national conference, hosted from November 10 – 12, 2022 in Salt Lake City, Utah, will focus on the utility of new technologies to improve wound care delivery and clinical outcomes. It will include a combination of nine clinical posters, a clinical talk and a hands-on workshop featuring the MolecuLight devices.
Also Read: World-Class Forum for Life Science Innovation CNS Summit Taps Cumulus Neuroscience
“The technological innovation surge in wound care is transforming how we practice. At the Technology in Wound Care conference, we bring together the most novel and impactful technologies to share evidence and clinician insights into how they improve treatment decisions and patient outcomes”, says Alisha Oropallo, MD, FACS, FSVS, FAPWCA, FABWMS, AAWC Conference Co-Chair and Medical Director of the Comprehensive Wound Healing Center and Hyperbarics at Northwell Health, New York. “MolecuLight has extensively validated their point-of-care imaging technology for detection of wound regions harboring clinically concerning bacterial loads and for digital wound measurement. They are a market leader and have set the standard of validation evidence for wound imaging technologies. As such, it is appropriate that MolecuLight is featured in so many clinical presentations, demonstrations, and posters, including over 1,800 new wounds’ worth of evidence being shown at this meeting. This innovative technology has become a standard of care in my practice, where it serves as an essential tool to inform and enhance our clinical decision-making.”
New evidence from MolecuLight to be presented at AAWC 2022 includes:
- validation of the role this technology can play in addressing racial inequities in wound infection assessment,
- real-world findings from providers across the US on the treatment plan changes and outcome improvements that result from the implementation of MolecuLight, and
- further validation of the device’s digital wound area measurement capability, which is now stickerless.